Massimo Negrini

Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.

Loss of methylation at chromosome 11p15.5 is common in human adult tumors.

NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).

Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors.

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Genetic chaos and antichaos in human cancers.

Human homeobox gene HOXC13 is the partner of NUP98 in adult acute myeloid leukemia with t(11;12)(p15;q13).

Oncogenic transformation by BK virus and association with human tumors.

The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene.

Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Simian virus 40 infection in humans and association with human diseases: results and hypotheses.

Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood.

An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues.

MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.

Cryptic insertion producing two NUP98/NSD1 chimeric transcripts in adult refractory anemia with an excess of blasts.

Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer.

Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo.

Familial cancer associated with a polymorphism in ARLTS1.

MicroRNA gene expression deregulation in human breast cancer.

miR-15 and miR-16 induce apoptosis by targeting BCL2.

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion.

Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene.

A microRNA expression signature of human solid tumors defines cancer gene targets.

BK virus, JC virus and Simian Virus 40 infection in humans, and association with human tumors.

Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer.

Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas.

Mechanisms causing imprinting defects in familial Beckwith-Wiedemann syndrome with Wilms' tumour.

A microRNA signature of hypoxia.

Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer.

MicroRNAs in human cancer: from research to therapy.

Regulation of microRNA expression: the hypoxic component.

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Regulatory mechanisms of microRNAs involvement in cancer.

Tumor suppressor functions of ARLTS1 in lung cancers.

mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer.

Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas.

Micro-RNA profiling in kidney and bladder cancers.

E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer.

MiR-15a and miR-16-1 cluster functions in human leukemia.

Breast cancer metastasis: a microRNA story.

Isolation and characterization of CD146+ multipotent mesenchymal stromal cells.

Genome wide identification of recessive cancer genes by combinatorial mutation analysis.

MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation.

MicroRNA involvement in hepatocellular carcinoma.

MicroRNAs and cancer--new paradigms in molecular oncology.

MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.

MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality.

Karyotype-specific microRNA signature in chronic lymphocytic leukemia.

MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis.

Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4.

Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment.

Modulation of mismatch repair and genomic stability by miR-155.

Micromarkers: miRNAs in cancer diagnosis and prognosis.

Oncogenic role of miR-483-3p at the IGF2/483 locus.

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.

Reprogramming of miRNA networks in cancer and leukemia.

MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.

Altered miRNA expression in T regulatory cells in course of multiple sclerosis.

Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia.

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

MicroRNAs dysregulation in human malignant pleural mesothelioma.

Mutated beta-catenin evades a microRNA-dependent regulatory loop.

MicroRNA response to environmental mutagens in liver.

microRNA involvement in hepatocellular carcinoma.

MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.

miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.

MicroRNAs: toward the clinic for breast cancer patients.

MINT31 methylation in gastric noninvasive neoplasia: potential role in the secondary prevention of gastric cancer.

Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters.

In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.

Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.

MicroRNA-mediated regulation of pancreatic cancer cell proliferation.

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.

Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25.

BCR/ABL1-positive acute lymphoblastic leukemia relapsing as BCR/ABL1-negative acute lymphoblastic leukemia.

miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma.

miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs.

CCAT2, a novel non-coding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.

STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia.

Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.

Role of microRNAs in hepatocellular carcinoma: a clinical perspective.

First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.

miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.

p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.

Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients.

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups.

microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.

OncomiR detection in circulating body fluids: a PDMS microdevice perspective.

Gene expression changes in progression of cervical neoplasia revealed by microarray analysis of cervical neoplastic keratinocytes.

Pluripotent stem cell miRNAs and metastasis in invasive breast cancer.

Mesenchymal progenitors aging highlights a miR-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis.

Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma.

Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries.

Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells.

Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.

Absolute quantification of cell-free microRNAs in cancer patients.

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR.

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.

Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis.

Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations.

Interspecies Gene Name Extrapolation--A New Approach.

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC.

MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.

miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.

Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma.

Dissecting chronic lymphocytic leukemia with 13q- using microRNA expression profile: Editorial for the paper "MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion".